AcelRx Announces Positive Phase 2 Results
AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical study evaluating the safety and efficacy of the ARX-02 Sufentanil NanoTabâ„¢ Breakthrough Pain Management System in the treatment of cancer breakthrough pain in opioid-tolerant patients.

Download PDF